Heptares Therapeutics Limited
USPTO PatentsView assignee record - 78 granted patents across 9 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Heptares ranks #4,517 of 49,997 tracked US assignees by granted-patent volume, with 78 patents across 9 technology areas.
- #4,517
- of 49,997 US assignees by volume
- Top 43%
- by Innovation Score (37.6/100)
- 15.4
- avg claims per patent
- -14%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R4517 · Foreign Corporation #4,517 · 78 grants
GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL
- GRANTS-SMALL 78 grants
- TOP-DECILE #4,517/49,997
- PHOTO-FINISH Grote Industries
- CPC-NARROW A61P · 9 areas
- INNOV-THIN 37.6/100
- CLAIMS-RICH 15.4 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DOWN -14% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Grote Industries, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Heptares’s 37.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Heptares
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Collision Communicat… · near
Collision Communicat… · near
38 score
- Heptares Therapeutics · this assignee
Heptares Therapeutics · this assignee
38 score
- Cosmo · near
Cosmo · near
38 score
- Shoretel · near
Shoretel · near
38 score
- Summit Glove · near
Summit Glove · near
38 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Heptares's Innovation Score is 37.6/100 (top 43% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Heptares?
Each dot is one of Heptares’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Heptares’s own 15.4 claims/patent is ABOVE the 15.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Heptares's grants concentrate
Heptares Therapeutics Limited is a focused PatentsView assignee: 9 CPC subclasses with 87.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (17 grants) versus a trough of 2 in 2015. By volume, Heptares sits between Grote Industries, Inc. and Keygene N.V..
Heptares's three-year grant acceleration
From 2019–2021 to 2022–2024, Heptares Therapeutics Limited moved from 38 to 15 grants (0.40x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.
Who files at Heptares's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Grote Industries
Grote Industries, Inc.
78 patents
- H B Fuller
H.B. Fuller Company
78 patents
- Hongfujin Precisi…
Hongfujin Precision Electronics (ZHENGZHOU) Co., Ltd.
78 patents
- Hanchett Entry Sy…
Hanchett Entry Systems, Inc.
78 patents
- Indian Institute…
Indian Institute OF Technology Bombay
78 patents
- Interrad Medical
Interrad Medical, Inc.
78 patents
- KAO Germany
KAO Germany GMBH
78 patents
- Keygene
Keygene N.V.
78 patents
- Heptares Therapeu… ◀
Heptares Therapeutics Limited
78 patents
What this shows Heptares holds 78 patents at rank #4,518, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Heptares
By rank, the assignees closest to #4,518 in granted patent volume.
- Grote Industries, Inc. #4,514 · 78 patents
- H.B. Fuller Company #4,515 · 78 patents
- Hongfujin Precision Electronics (ZHENGZHOU) Co., Ltd. #4,516 · 78 patents
- Hanchett Entry Systems, Inc. #4,517 · 78 patents
- Indian Institute OF Technology Bombay #4,519 · 78 patents
- Interrad Medical, Inc. #4,520 · 78 patents
- KAO Germany GMBH #4,521 · 78 patents
- Keygene N.V. #4,522 · 78 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Heptares's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Heptares, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Heptares ranks #251 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (38 here).
Similar claim depth
Nearest assignees by average claims per patent (15.4 here).
Heptares's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
38 Top 43% higher than 57% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 2.6% |
| 2016 | 4 | 5.1% |
| 2017 | 11 | 14.1% |
| 2018 | 8 | 10.3% |
| 2019 | 17 | 21.8% |
| 2020 | 12 | 15.4% |
| 2021 | 9 | 11.5% |
| 2022 | 5 | 6.4% |
| 2023 | 6 | 7.7% |
| 2024 | 4 | 5.1% |
Which technologies does Heptares Therapeutics Limited patent most?
Top 9 of 9 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Heptares Therapeutics Limited's patent record in context - here's where to go next.
- Heptares Therapeutics Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.2% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #4,517 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Heptares Therapeutics Limited against Grote Industries, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 37.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.